TB-500 (Thymosin Beta-4) 10mg

Overview

TB-500 is a synthetic peptide fragment reproducing the active domain of Thymosin β4 (Tβ4), a 43-amino-acid protein among the most abundant actin-binding proteins in mammalian cells.

Mechanism of action

The active domain (sequence LKKTETQ) sequesters monomeric G-actin and regulates its polymerisation into F-actin filaments. In research, this promotes cell migration and angiogenesis, and modulates inflammation in repair processes.

Research context

Thymosin β4 has been the subject of clinical trials by RegeneRx Biopharmaceuticals under the designations RGN-259 (ophthalmic: dry eye, corneal healing) and RGN-352 (post-infarction cardiac repair). TB-500 itself remains studied primarily in preclinical research.

Quality assurance

• Purity ≥ 99 % verified by HPLC
• Certificate of Analysis (COA) available per batch
• Traceability: unique batch number on every vial

Format & handling

Presentation: lyophilised powder, 10 mg / vial · Reconstitution: bacteriostatic water · Storage: refrigerate the lyophilisate; after reconstitution, keep cold and protected from light.

References

• Thymosin β4 clinical programmes (RGN-259 / RGN-352), RegeneRx Biopharmaceuticals.
• « Thymosin Beta-4 and TB-500 in Tissue Healing and Musculoskeletal Repair: A Scoping Review », 2025.